OncoTargets and Therapy
Volume 13, 2020 - Issue
Open access
138
Views
18
CrossRef citations to date
0
Altmetric
Review
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
Hong Zhou1 Department of Oncology, Affiliated Hospital of Nantong University, Nantong226001, Jiangsu, People’s Republic of Chinahttps://orcid.org/0000-0002-4523-0219
, Pan Hu1 Department of Oncology, Affiliated Hospital of Nantong University, Nantong226001, Jiangsu, People’s Republic of China
, Xiyue Yan1 Department of Oncology, Affiliated Hospital of Nantong University, Nantong226001, Jiangsu, People’s Republic of China
, Yaping Zhang2 Department of Hematology, Affiliated Hospital of Nantong University, Nantong226001, Jiangsu, People’s Republic of Chinahttps://orcid.org/0000-0003-3381-1486
& Wenyu Shi1 Department of Oncology, Affiliated Hospital of Nantong University, Nantong226001, Jiangsu, People’s Republic of China;2 Department of Hematology, Affiliated Hospital of Nantong University, Nantong226001, Jiangsu, People’s Republic of ChinaCorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-2371-3332
https://orcid.org/0000-0002-2371-3332
Pages 4877-4892
|
Published online: 29 May 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.